Comparison of 208‐week sequential therapy with telbivudine and entecavir in HBeAg‐positive chronic hepatitis B patients with suboptimal responses to 24 weeks of Peg‐IFNα‐2a therapy: An open‐labelled, randomized, controlled, “real‐life” trial

    loading  Checking for direct PDF access through Ovid

Abstract

Abstract unavailable for this article.

Related Topics

    loading  Loading Related Articles